Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Bioanalysis
|
April 19, 2019
Perspectives on gender parity in bioanalysis: an interview with Lauren Stevenson
Lauren F Stevenson
Bioanalysis
|
May 15, 2026
From tiers to truth - a biomarker-based framework for clinically relevant immunogenicity assessment
Lauren F Stevenson
Bioanalysis
|
May 27, 2026
Immunogenicity assays are biomarker assays: is the 3-tiered paradigm fit-for-purpose? An illustrative case study
Lauren F Stevenson
Bioanalysis
|
January 16, 2014
Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays
Lauren F Stevenson, Shobha Purushothama
Bioanalysis
|
May 5, 2026
Rethinking immunogenicity: an integrated approach reveals the PK/PD impact of pre-existing and drug-sustaining ADA
Devangi Mehta, William Wargin, Stephanie Wallace-Teliz, et al.
Bioanalysis
|
December 13, 2019
Well-developed ligand-binding assays demonstrate robust performance using singlet analysis
Douglas Donaldson, Shobha Purushothama, Eric David, et al.
The EMBO Journal
|
February 10, 2007
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2
Lauren F Stevenson, Alison Sparks, Nerea Allende-Vega, et al.
The Journal of Biological Chemistry
|
July 29, 2004
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo
Mark K Saville, Alison Sparks, Dimitris P Xirodimas, et al.
The AAPS Journal
|
January 8, 2014
Large molecule run acceptance: Recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team
Marian Kelley, Christopher Beaver, Lauren F Stevenson, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Bioanalysis
|
April 19, 2019
Perspectives on gender parity in bioanalysis: an interview with Lauren Stevenson
Lauren F Stevenson
Bioanalysis
|
May 15, 2026
From tiers to truth - a biomarker-based framework for clinically relevant immunogenicity assessment
Lauren F Stevenson
Bioanalysis
|
May 27, 2026
Immunogenicity assays are biomarker assays: is the 3-tiered paradigm fit-for-purpose? An illustrative case study
Lauren F Stevenson
Bioanalysis
|
January 16, 2014
Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays
Lauren F Stevenson, Shobha Purushothama
Bioanalysis
|
May 5, 2026
Rethinking immunogenicity: an integrated approach reveals the PK/PD impact of pre-existing and drug-sustaining ADA
Devangi Mehta, William Wargin, Stephanie Wallace-Teliz, et al.
Bioanalysis
|
December 13, 2019
Well-developed ligand-binding assays demonstrate robust performance using singlet analysis
Douglas Donaldson, Shobha Purushothama, Eric David, et al.
The EMBO Journal
|
February 10, 2007
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2
Lauren F Stevenson, Alison Sparks, Nerea Allende-Vega, et al.
The Journal of Biological Chemistry
|
July 29, 2004
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo
Mark K Saville, Alison Sparks, Dimitris P Xirodimas, et al.
The AAPS Journal
|
January 8, 2014
Large molecule run acceptance: Recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team
Marian Kelley, Christopher Beaver, Lauren F Stevenson, et al.
Page
of 1